Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol 2019;20:769–780.
Del Paggio JC, Azariah B, Sullivan R, et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann Oncol 2017;28:157–162.
Lawrence NJ, Roncolato F, Martin A, et al. Effect sizes hypothesized and observed in contemporary phase III trials of targeted and immunological therapies for advanced cancer. JNCI Cancer Spectr 2018;2:pky037.
Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014;140:1225–1236.
- Search Google Scholar
- Export Citation
, Fojo T , Mailankody S Lo A Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014; 140: 1225– 1236. 10.1001/jamaoto.2014.1570
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019;20:273–286.
Food and Drug Administration Amendments Act of 2007. Pub L No. 110-85, § 801, 121 Stat 823.
Zarin DA, Tse T, Menikoff J. Federal human research oversight of clinical trials in the United States. JAMA 2014;311:960–961.
Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031–1039.
Anderson ML, Peterson ED. Compliance with results reporting at ClinicalTrials.gov [letter]. N Engl J Med 2015;372:2370–2371.
Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst 2011;103:16–20.
Shen C. Interval estimation of a population mean using existing knowledge or data on effect sizes. Stat Methods Med Res 2019;28:1703–1715.
Shen C, Li X. Using previous trial results to inform hypothesis testing of new interventions. J Biopharm Stat 2018;28:884–892.
Chen YP, Liu X, Lv JW, et al. Publication status of contemporary oncology randomised controlled trials worldwide. Eur J Cancer 2016;66:17–25.
Benjamin DJ, Berger JO, Johannesson M, et al. Redefine statistical significance. Nat Hum Behav 2018;2:6–10.
Wayant C, Scott J, Vassar M. Evaluation of lowering the P value threshold for statistical significance from .05 to .005 in previously published randomized clinical trials in major medical journals. JAMA 2018;320:1813–1815.
Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs [letter]. JAMA Oncol 2015;1:539–540.
Vreman RA, Belitser SV, Mota ATM, et al. Efficacy gap between phase II and subsequent phase III studies in oncology. Br J Clin Pharmacol 2020;86:1306–1313.